Esomeprazole or Pantoprazole in Renal Transplantation
Status:
Completed
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
prospective, parallel, open-label clinical trial was performed on forty-seven adult renal
transplant recipients receiving immunosuppressive therapy with CsA doses adjusted to attain
trough concentrations of 100-150 μg/L, mycophenolate mofetil (MMF) at 750 mg q12 hr and
prednisolone at 5 mg daily randomized into two groups, which received esomeprazole or
pantoprazole at the same dose (40 mg once daily). To compare the influence of pantoprazole
and esomeprazole on serum cyclosporine (CsA) levels in stable renal transplant
recipients.Cyclosporine (C0), renal function and complete blood count were measured at
baseline and for 6 months. Main outcome measures Clinical signs of rejection and renal
function decline, assessed by serum creatinine elevations, caused by CsA level variations in
either of the study groups.
Phase:
N/A
Details
Lead Sponsor:
Future University in Egypt
Collaborators:
Ain Shams University Nasser Institute For Research and Treatment